LFST LifeStance Health Group, Inc.companySEC Filings & Insider Trading Activity 2026
Latest LifeStance Health Group, Inc. (LFST) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 11, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for LifeStance Health Group, Inc. (LFST) (SEC CIK 1845257), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Nationwide outpatient mental healthcare platform employing 8,040 clinicians across 33 states with integrated virtual and in-person care
- • Strategic shift: Prioritized virtual visits leading to significant reduction of physical office footprint and closure of underoccupied centers in 2023
Risk Factors
- • Regulatory risk from the No Surprises Act (effective Jan 1, 2022) causing payment disputes and penalties for billing and provider directory inaccuracies
- • Geopolitical/macroeconomic exposure from 29% revenue concentration with UnitedHealthcare (14%) and Elevance Health (15%), risking impact from reimbursement changes
Management Discussion & Analysis
- • Cash and cash equivalents $248.6M in 2025 vs $154.6M in 2024; operating cash flow $146.2M in 2025 vs $107.3M in 2024
- • Debt outstanding $282.8M in 2025 vs $290.0M in 2024 under 2024 Credit Agreement; compliance with leverage and interest coverage covenants
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: Impact of One Big Beautiful Bill Act (OBBBA) enacted July 4, 2025, with changes to Medicaid renewal and eligibility, effective 2027-2028, currently not materially impacting business
- • Updated risk: Payor contract renegotiations may lower reimbursement rates, risking revenue due to dependency on significant payors for patient service revenue
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Lisa Miller promoted to COO effective March 10, 2026, previously EVP Practice Operations since Feb 2024 — internal promotion signals continuity
- • Annual base salary set at $485,000 with target bonus of 85% of base (~$412,250), implying total cash target ~$897,250
Item 8.01: Other Events
- • Selling stockholders offloaded 25M shares via underwritten offering — zero proceeds to LFST, signaling insider/sponsor liquidation
- • LFST simultaneously repurchasing 7M of those shares from underwriter at same price paid to selling stockholders — no underwriter compensation on buyback portion
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full year 2025 earnings results released Feb 25, 2026
- • Full financial details in Exhibit 99.1 press release — key figures not disclosed in filing body
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Kenneth Burdick stepping down as Executive Chairman → non-executive Chairman effective March 16, 2026
- • Post-transition comp: $200K annual cash retainer + ~$500K annual RSU grant as non-executive chair
Item 7.01: Regulation FD Disclosure
- • Supplemental slide deck filed as Exhibit 99.2 — primary source for any new operational or financial data disclosed under Reg FD
- • Reg FD filing ensures institutional and retail investors receive material information simultaneously — watch Exhibit 99.2 for guidance, metrics, or strategic updates
Item 8.01: Other Events
- • Board approved $100M share repurchase program on Feb 24, 2026
- • No obligation to repurchase any specific amount — purely discretionary and open-ended
Annual Reports Archive10-K
AI-powered analysis of LifeStance Health Group, Inc. (LFST) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of LifeStance Health Group, Inc. (LFST) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of LifeStance Health Group, Inc. (LFST) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $859.5M | $1.1B | $1.3B | $1.4B |
| Operating Income | -$210.2M | -$189.1M | -$31.6M | $24.1M |
| Net Income | -$215.6M | -$186.3M | -$57.4M | $9.7M |
| Op. Margin | -24.5% | -17.9% | -2.5% | 1.7% |
| Net Margin | -25.1% | -17.6% | -4.6% | 0.7% |
| Balance Sheet | ||||
| Total Assets | $2.2B | $2.1B | $2.1B | $2.2B |
| Equity | $1.5B | $1.4B | $1.4B | $1.5B |
| ROE | -14.2% | -13.0% | -4.0% | 0.6% |
Source: XBRL financial data from LifeStance Health Group, Inc. (LFST) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 11, 2026 | — | Analysis | — |
8-K | Mar 2, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 25, 2026 | — | Analysis | — |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 7, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 10, 2023 | Mar 31, 2023 | — | |
10-K | Mar 9, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 10, 2022 | Jun 30, 2022 | — | |
10-Q | May 11, 2022 | Mar 31, 2022 | — | |
10-K | Mar 17, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 12, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest LFST SEC filings in 2026?
LifeStance Health Group, Inc. (LFST) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 11, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did LFST file its most recent 10-K annual report?
LifeStance Health Group, Inc. (LFST) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view LFST 10-Q quarterly reports?
LifeStance Health Group, Inc. (LFST)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every LFST 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has LFST filed recently?
LifeStance Health Group, Inc. (LFST)'s most recent 8-K was filed on March 11, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find LFST insider trading activity (Form 4)?
SignalX aggregates every LFST Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does LFST file with the SEC?
LifeStance Health Group, Inc. (LFST) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LFST filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for LifeStance Health Group, Inc. (LFST).
What is LFST's SEC CIK number?
LifeStance Health Group, Inc. (LFST)'s SEC CIK (Central Index Key) number is 1845257. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1845257 to look up all LFST filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find LFST return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from LifeStance Health Group, Inc. (LFST) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of LifeStance Health Group, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 22+ filings.